Mariner’s Lucid Diagnostics LUCD Stock Holding History
Bought
Maintained
Sold
Other funds holding LUCD
TSC
MCM
Mariner's LUCD Position: Q2 2026 in Review
Mariner increased its Lucid Diagnostics (LUCD) stake by 104% in Q2 2026, buying an estimated $23.7K and bringing the position to 43,146 shares worth $46.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3419.
Mariner first reported a position in LUCD in Q1 2025 and has held it in 4 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.
- Mariner held 43,146 shares of Lucid Diagnostics worth $46.2K as of Q2 2026.
- Mariner bought 21,993 Lucid Diagnostics shares in Q2 2026, an estimated $23.7K.
- Lucid Diagnostics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3419 holding.
- Mariner first reported a position in Lucid Diagnostics in Q1 2025 and has held it in 4 quarters since.
- 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.
Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.